Latest Information Update: 19 Apr 2016
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
- 01 Nov 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy, Combination therapy) in USA (PO)
- 19 Oct 2015 AstraZeneca plans a phase I trial for Solid tumours in USA, South Korea, Spain and United Kingdom (PO) (NCT02588105)